The John L. Scott Foundation helps support Seattle Children’s
Seattle Children’s | Casey Egan
Seattle Children’s has received FDA authorization to launch the first chimeric antigen receptor (CAR) T-cell clinical trial in the U.S. for children under 18 with the most common form of lupus.
Systemic lupus erythematosus is a chronic autoimmune disorder that affects multiple organ systems, resulting in significant morbidity and mortality. Approximately 20% of lupus patients have disease onset during childhood, and children with lupus are at particular risk for severe disease and worse long-term outcomes.
Read the full article: Seattle Children’s Set to Launch First U.S. CAR T-Cell Clinical Trial for Children with Lupus
